Evaluating the Safety, Tolerability, Pharmacokinetics and Receptor Occupancy of BMS-984923

Conditions

Men's Health | Women's Health

Volunteers
Health Professionals

What is the purpose of this trial?

This project seeks to develop a novel disease-modifying compound for Alzheimer's disease (AD).

Ages
50 years - 80 years
Gender
Both

Find out more about who can participate in this trial

Trial with
Alzheimer's Association
Start Date
03/25/2021
End Date
06/01/2022

For more information about this study, contact:

Monica Canning-Ball

monica.canning-ball@yale.edu

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

Volunteer Now

Principal Investigator

Adam Mecca, MD, PhD
Assistant Professor of Psychiatry; Associate Director, Alzheimer's Disease Research Unit; Faculty, Alzheimer's Disease Research Center (ADRC)

Sub-Investigators

Christopher Van Dyck, MD
David Matuskey, MD
Gustavo A. Angarita, MD
Ming-Kai Chen, MD, PhD
Stephen Strittmatter, MD, PhD, AB

Last Updated
06/26/2022
Study HIC
#2000028864

Evaluating the Safety, Tolerability, Pharmacokinetics and Receptor Occupancy of BMS-984923

Conditions

Volunteers

Health Professionals

What is the purpose of this trial?

I'm interested in volunteering

Principal Investigator

Sub-Investigators

Contact Information